Connecting in a Volatile Job Market
What is the correct metaphor for today’s biopharma job market? A…
A Practical Guide to Biopharma Year-End Planning
As summer winds down and vacations (sadly) come to an end, it’s a natural time…
Building Credibility as a New Leader
Credibility is essential for leaders in any industry, but in the high-stakes…
BIO and Boston: The Global Stage and HLYB
Attending a large conference, medical congress, or trade show can be both…
The Power of Key Business Questions
In our biopharma world, we frequently hear the term “Key Business Questions (KBQs).” And while it’s often thrown around as a buzzword (or buzz…
The Underappreciated Value of New Product Planning
The value of New Product Planning (NPP) is often overlooked, but it plays a crucial role in the success of drug development projects. By…
Biopharma Annual Planning Success: Close Your Rings Year-Round
How do we think about biopharma annual planning differently? The analogy we will draw on is fitness trackers and apps—built for mindfulness and…
The Power of Target Product Profiles: Three Case Studies
In the biopharma industry, the Target Product Profile (TPP) is a critical tool for guiding the development and commercialization of new drugs.
Unlocking Success: The Power of Target Product Profiles
In the ever-evolving biopharma landscape, success hinges not just on innovation but also on a clear roadmap guiding clinical and commercial…
Unfinished Business on the Glass Ceiling
Reflecting on my career and the significant societal and technological shifts during those years, I see it as split between two generations, each…
Governance: The Glue to a Successful Launch
At the core of every successful launch lies a meticulously crafted plan, a robust governance structure, and expert management of its execution.
Your Biopharma Data Needs a Strategy
In the not-so-distant past, physician prescribing data was essentially a commodity with limited breadth or depth for the purposes of drug development…
Success in Rare Disease: Patient Involvement Matters!
This past December, the FDA finalized its guidance on rare diseases with the publication Rare Diseases: Considerations for the Development of Drugs…
Juggling Geographic Commercialization Priorities
Commercializing a pharmaceutical asset in one country is hard enough. Doing it on a global scale, with multiple country differences, is exponentially…